Loading...
XNASMTEM
Market cap905kUSD
Dec 24, Last price  
0.10USD
1D
-14.06%
1Q
-89.17%
Jan 2017
-99.81%
IPO
-100.00%
Name

Molecular Templates Inc

Chart & Performance

D1W1MN
XNAS:MTEM chart
P/E
—
P/S
0.01
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
17.93%
Rev. gr., 5y
51.07%
Revenues
57m
+190.10%
0690,0001,461,0001,436,0001,440,0001,440,000062,0005,867,00012,495,00014,722,00076,915,0001,880,0002,408,0007,283,00019,499,00015,635,00038,697,00019,754,00057,306,000
Net income
-8m
L-91.24%
-23,566,000-44,408,000-55,686,000-30,664,000-18,292,000-23,648,000-18,682,000-25,653,000-71,135,000-28,415,000-21,584,00043,822,000-24,094,000-23,140,000-30,287,000-69,537,000-104,916,000-79,314,000-92,718,000-8,124,000
CFO
-42m
L-53.02%
-10,800,000-29,879,000-46,424,000-29,245,000-16,308,000-17,785,000-22,384,000-23,851,00029,913,00010,151,000-27,735,000-38,003,000-25,099,000-14,264,000-4,465,000-25,244,000-83,797,000-30,387,000-89,024,000-41,820,000
Earnings
Mar 27, 2025

Profile

Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases. The company primarily develops a pipeline of therapies through its proprietary biologic engineered toxin body (ETB) drug platform. The company is developing MT-5111, an ETB candidate that is in Phase I clinical trial for the treatment of HER2-positive cancers; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory myeloma patients; and MT-6402 in that is in Phase I clinical trial for PD-1/PD-L1 antibody relapsed/refractory patients. Its pipeline of ETBs in development for other targets, including CTLA-4, TIGIT, TROP2, BCMA, SLAMF-7, and CD45. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.
URL
https://mtem.com/
IPO date
Feb 04, 2005
Employees
111
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
57,306
190.10%
19,754
-48.95%
38,697
147.50%
Cost of revenue
74,683
116,425
125,471
Unusual Expense (Income)
NOPBT
(17,377)
(96,671)
(86,774)
NOPBT Margin
Operating Taxes
(11)
53
(3,695)
Tax Rate
NOPAT
(17,366)
(96,724)
(83,079)
Net income
(8,124)
-91.24%
(92,718)
16.90%
(79,314)
-24.40%
Dividends
Dividend yield
Proceeds from repurchase of equity
18,383
33
72,765
BB yield
-109.49%
-0.18%
-33.57%
Debt
Debt current
2,488
2,182
2,606
Long-term debt
21,972
60,630
54,619
Deferred revenue
5,904
33,350
Other long-term liabilities
4,108
1,295
1,625
Net debt
11,622
(726)
(94,805)
Cash flow
Cash from operating activities
(41,820)
(89,024)
(30,387)
CAPEX
(200)
(3,198)
(3,996)
Cash from investing activities
29,095
95,317
(62,440)
Cash from financing activities
(9,116)
(265)
92,592
FCF
(8,156)
(94,571)
(77,638)
Balance
Cash
11,523
61,049
143,044
Long term investments
1,315
2,489
8,986
Excess cash
9,973
62,550
150,095
Stockholders' equity
(452,887)
(444,778)
(352,042)
Invested Capital
473,437
487,426
500,340
ROIC
ROCE
EV
Common stock shares outstanding
4,501
3,756
3,687
Price
3.73
-24.19%
4.92
-91.63%
58.80
-58.25%
Market cap
16,789
-9.14%
18,478
-91.48%
216,767
-51.51%
EV
28,411
17,752
121,962
EBITDA
(10,732)
(89,288)
(80,144)
EV/EBITDA
Interest
2,654
4,782
3,369
Interest/NOPBT